Russell Investments Group Ltd. trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 50.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,216 shares of the company’s stock after selling 36,886 shares during the quarter. Russell Investments Group Ltd. owned 0.08% of Amphastar Pharmaceuticals worth $1,358,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Bank of Montreal Can increased its holdings in shares of Amphastar Pharmaceuticals by 2.9% in the 1st quarter. Bank of Montreal Can now owns 13,029 shares of the company’s stock valued at $477,000 after acquiring an additional 371 shares during the period. Arizona State Retirement System boosted its holdings in shares of Amphastar Pharmaceuticals by 4.2% in the 4th quarter. Arizona State Retirement System now owns 11,064 shares of the company’s stock valued at $310,000 after buying an additional 448 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of Amphastar Pharmaceuticals by 2.1% in the 1st quarter. Raymond James & Associates now owns 23,561 shares of the company’s stock valued at $884,000 after buying an additional 483 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 2.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,715 shares of the company’s stock valued at $496,000 after buying an additional 488 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 6.8% in the 4th quarter. ProShare Advisors LLC now owns 10,023 shares of the company’s stock valued at $281,000 after buying an additional 637 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 36,868 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $50.85, for a total value of $1,874,737.80. Following the completion of the transaction, the chief financial officer now owns 105,603 shares in the company, valued at $5,369,912.55. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Howard Lee sold 16,679 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $45.02, for a total value of $750,888.58. Following the completion of the sale, the director now directly owns 142,939 shares in the company, valued at $6,435,113.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO William J. Peters sold 36,868 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $50.85, for a total value of $1,874,737.80. Following the completion of the sale, the chief financial officer now owns 105,603 shares of the company’s stock, valued at $5,369,912.55. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 118,122 shares of company stock worth $6,001,690. Corporate insiders own 27.80% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have recently weighed in on AMPH. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Jefferies Financial Group began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, July 25th. They set a “buy” rating and a $70.00 price target for the company. Finally, Piper Sandler lifted their price target on Amphastar Pharmaceuticals from $66.00 to $71.00 in a research report on Wednesday, August 9th.
View Our Latest Research Report on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Price Performance
Shares of AMPH opened at $53.63 on Wednesday. The business’s 50-day moving average is $57.63 and its two-hundred day moving average is $46.11. The company has a market capitalization of $2.59 billion, a P/E ratio of 27.50 and a beta of 0.82. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.11 and a current ratio of 1.53. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $67.66.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06. Amphastar Pharmaceuticals had a return on equity of 20.12% and a net margin of 18.85%. The business had revenue of $145.71 million for the quarter, compared to analyst estimates of $137.20 million. Research analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.5 earnings per share for the current year.
Amphastar Pharmaceuticals Profile
(Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
Further Reading
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amphastar Pharmaceuticals wasn’t on the list.
While Amphastar Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.
Get This Free Report